SEC 13F Intelligence

Capital Research Global Investors / BMRN

Capital Research Global Investors’s Biomarin Pharmaceutical Inc Position

Does Capital Research Global Investors own Biomarin Pharmaceutical Inc (BMRN)? Yes — 3.49M shares worth $197M (+0.03% of its 13F portfolio) as of Q1 2026, up from 2.55M shares the prior filed quarter.

Position Value
$197M
Q1 2026
Shares
3.49M
% of Portfolio
+0.03%
Quarters Held
30
currently held

Position History BMRN

Reported value by quarter
Q4 ’18: $1.6BQ4 ’18Q1 ’19: $1.6BQ2 ’19: $1.7BQ3 ’19: $1.5BQ4 ’19: $1.9BQ4 ’19Q1 ’20: $1.9BQ2 ’20: $2.7BQ3 ’20: $1.7BQ4 ’20: $1.9BQ4 ’20Q1 ’21: $1.7BQ2 ’21: $1.8BQ3 ’21: $1.4BQ4 ’21: $1.1BQ4 ’21Q1 ’22: $724MQ2 ’22: $409MQ3 ’22: $418MQ4 ’22: $585MQ4 ’22Q1 ’23: $701MQ2 ’23: $586MQ3 ’23: $532MQ4 ’23: $1.0BQ4 ’23Q1 ’24: $570MQ2 ’24: $798MQ3 ’24: $738MQ4 ’24: $854MQ4 ’24Q1 ’25: $647MQ2 ’25: $22MQ3 ’25: $137MQ4 ’25: $151MQ4 ’25Q1 ’26: $197Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 20263.49M$197M+0.03%
Q4 20252.55M$151M+0.03%
Q3 20252.54M$137M+0.03%
Q2 2025391.9K$22M0.00%
Q1 20259.15M$647M+0.14%
Q4 202412.99M$854M+0.18%
Q3 202410.49M$738M+0.15%
Q2 20249.69M$798M+0.18%
Q1 20246.52M$570M+0.13%
Q4 202310.77M$1.0B+0.26%
Q3 20236.02M$532M+0.15%
Q2 20236.76M$586M+0.16%
Q1 20237.21M$701M+0.20%
Q4 20225.65M$585M+0.18%
Q3 20224.94M$418M+0.14%
Q2 20224.94M$409M+0.13%
Q1 20229.39M$724M+0.18%
Q4 202112.67M$1.1B+0.25%
Q3 202117.65M$1.4B+0.32%
Q2 202122.09M$1.8B+0.43%
Q1 202122.08M$1.7B+0.41%
Q4 202022.08M$1.9B+0.50%
Q3 202022.06M$1.7B+0.50%
Q2 202022.07M$2.7B+0.86%
Q1 202022.04M$1.9B+0.73%
Q4 201922.00M$1.9B+0.56%
Q3 201921.71M$1.5B+0.48%
Q2 201919.70M$1.7B+0.54%
Q1 201917.75M$1.6B+0.50%
Q4 201818.30M$1.6B+0.54%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Capital Research Global Investors’s full portfolio or all institutional holders of BMRN.